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Abstract
This study tested whether chronic systemic administration of 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside
(AICAR) could attenuate hyperphagia, reduce lean and fat mass losses, and improve whole-body energy homeostasis in
insulin-deficient rats. Male Wistar rats were first rendered diabetic through streptozotocin (STZ) administration and then
intraperitoneally injected with AICAR for 7 consecutive days. Food and water intake, ambulatory activity, and energy
expenditure were assessed at the end of the AICAR-treatment period. Blood was collected for circulating leptin
measurement and the hypothalami were extracted for the determination of suppressor of cytokine signaling 3 (SOCS3)
content, as well as the content and phosphorylation of AMP-kinase (AMPK), acetyl-CoA carboxylase (ACC), and the signal
transducer and activator of transcription 3 (STAT3). Rats were thoroughly dissected for adiposity and lean body mass (LBM)
determinations. In non-diabetic rats, despite reducing adiposity, AICAR increased (,1.7-fold) circulating leptin and reduced
hypothalamic SOCS3 content and food intake by 67% and 25%, respectively. The anorexic effect of AICAR was lost in
diabetic rats, even though hypothalamic AMPK and ACC phosphorylation markedly decreased in these animals. Importantly,
hypothalamic SOCS3 and STAT3 levels remained elevated and reduced, respectively, after treatment of insulin-deficient rats
with AICAR. Diabetic rats were lethargic and displayed marked losses of fat and LBM. AICAR treatment increased ambulatory
activity and whole-body energy expenditure while also attenuating diabetes-induced fat and LBM losses. In conclusion,
AICAR did not reverse hyperphagia, but it promoted anti-catabolic effects on skeletal muscle and fat, enhanced
spontaneous physical activity, and improved the ability of rats to cope with the diabetes-induced dysfunctional alterations
in glucose metabolism and whole-body energy homeostasis.
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Introduction
Insulin is a key player in the control of intermediary metabolism
with widespread effects on food intake, body composition, and
whole-body energy homeostasis [1]. Under conditions of insulin
deficiency, such as in type 1 diabetes (T1D), a myriad of complex
and interactive dysfunctional metabolic alterations take place [2].
Pronounced loss of muscle and fat mass, hyperphagia, polydipsia,
polyuria, hyperglycemia, and ketoacidosis are typical manifesta-
tions of insulin deficiency found in T1D [1,2]. The administration
of exogenous insulin corrects these dysfunctional metabolic
alterations and remains the main therapeutic approach for the
treatment of T1D [1,2]. However, the challenge in the therapy of
T1D is to precisely match insulin administration with dietary
carbohydrate intake to tightly maintain euglycemia in the long-
term [2]. Therefore, alternative pharmacological approaches have
been tested either alone or in combination with insulin in an
attempt to improve glycemic control and prevent multiple
complications of diabetes [3]. In this context, several studies have
investigated the effectiveness of pharmacological agents that
activate the cellular energy sensor AMP-activated protein kinase
(AMPK) in diabetes therapy [4–6]. AMPK is a heterotrimeric
enzyme that can be allosterically and covalently [7,8] activated
under conditions of metabolic stresses (e.g. exercise, glucose
deprivation, etc) that increase intracellular AMP, ADP or Ca2+
[7].
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In its activated state, AMPK turns on catabolic pathways that
increase ATP synthesis while simultaneously suppressing energy-
consuming biosynthetic pathways in an attempt to restore the
energy charge of cells [7]. A drug extensively used to study the
effects of acute and chronic AMPK activation in various cells and
tissues in vitro or in vivo is the AMP analog AICAR, which induces
AMPK activation without altering the intracellular AMP:ATP
ratio [9]. In peripheral tissues such as skeletal muscle, AICAR-
induced AMPK activation has been extensively demonstrated to
increase glucose uptake, glycogen synthesis, and fatty acid
oxidation [3–5,10–14]. When administered directly into the brain,
AICAR induces hypothalamic AMPK activation which, in turn,
phosphorylates/de-activates its downstream target acetyl CoA
carboxylase (ACC), leading to an orexigenic effect [15–17].
Interestingly, we have previously demonstrated that intraperito-
neal (i.p.) administration of AICAR reduced hypothalamic AMPK
phosphorylation and increased ambulatory activity and whole-
body energy expenditure in lean rats. Additionally, a significant
reduction in food intake was observed in these animals [18]. These
findings provided evidence that antagonistic effects on food intake
could be achieved depending on whether AICAR was centrally or
systemically administered. Moreover, the anorexic response to
exogenous leptin has been reported to be exacerbated in rats
chronically receiving i.p. AICAR injections [18], providing
evidence that systemically administered AICAR actually causes a
leptin-sensitizing effect.
Leptin exerts anorexic effects through mechanisms that involve
inhibition of AMPK activation in the hypothalamus [19]. Upon
binding to its receptors, leptin induces phosphorylation of STAT3,
which then undergoes homodimerization and translocation into
the nucleus. Through this cascade of events, leptin enhances and
suppresses the expression of anorexigenic and orexigenic genes,
respectively [19]. It also promotes the expression of SOCS3, which
serves as a negative feedback regulator of leptin signaling.
Therefore, while activation of AMPK in the hypothalamus
induces food intake and favors weight gain, inhibition of this
kinase by leptin blocks these centrally-mediated effects on energy
balance [19,20]. Based on these observations, we hypothesized
that systemically administered AICAR could actually attenuate the
hyperphagia that is typically associated with insulin deficiency [2].
This could be achieved through AICAR-induced inhibition of
AMPK activation and reduction of SOCS3 content in the
hypothalamus, as previously reported by us [18]. These central-
ly-mediated effects of systemic AICAR administration could also
alter body composition and whole-body energy homeostasis in a
way that ameliorates dysfunctional alterations of T1D. In order to
test this hypothesis, rats were rendered diabetic through the
administration of the pancreatic-b-cell-toxic drug streptozotocin
[21]. Diabetic animals with almost undetectable levels of
circulating insulin and severely hyperglycemic were then treated
for 7 consecutive days with AICAR as recently described by us
[14]. The results of this study provide novel evidence that AICAR
triggered selective anti-catabolic effects on skeletal muscle and
adipose tissue with important implications for spontaneous
physical activity and whole-body energy balance in diabetic rats.
Furthermore, analysis of hypothalamic content and phosphoryla-
tion of proteins involved in leptin signaling revealed molecular
mechanisms underlying the differences in food intake response
found between control and diabetic rats upon systemic AICAR
administration.
Materials and Methods
Animals
Male albino rats from the Wistar strain (Charles River
Laboratories, Montreal, Quebec, Canada) weighing 180–200 g
(initial weight) were used in all experiments. The animals were
housed in cages with free access to water and standard rat chow
(60, 27, and 13% of calories from carbohydrate, protein, and fat,
respectively, energy density 3.43 kcal/g, TestDiet Richmond, IN).
The animals were maintained in a constant-temperature (23uC),
with a fixed 12-h light, 12-h dark cycle (07:00–19:00 h). The
protocol containing all animal procedures described in this study
were specifically approved by the Committee on the Ethics of
Animal Experiments of York University (York University Animal
Care Committee, YUACC, permit number: 2011-14) and
performed strictly in accordance with the YUACC guidelines.
All surgery was performed under Ketamine/Xylazine anesthesia,
and all efforts were made to ensure that the animals did not suffer
unduly during and after the experimental procedure.
Reagents
AICAR was purchased from Toronto Research Chemicals
(Toronto, Ontario). STZ was obtained from Sigma (St. Louis,
MO). Specific antibodies against AMPK, P-AMPK (Thr172),
ACC, STAT3, P-STAT3, SOCS3, and GAPDH were purchased
from Cell Signaling Technology Inc. (Beverly, MA). The anti-P-
ACC (Ser 79) antibody was purchased from Millipore (Temecula,
CA).
STZ-induced Diabetes
Male Wistar rats (180–200 g) were fasted overnight and then
rendered diabetic by a single intraperitoneal (i.p.) injection of STZ
(65 mg/kg BW). Following the STZ injection, animals had ad
libitum access to food and water. Fourty eight hours post-STZ
injection, blood was drawn from the saphenous vein to measure
glycemia using the LifeScan OneTouch Ultra glucometer. Only
animals eliciting plasma glucose levels equal or greater than
25 mmol/l were used in this study. This was confirmed by
measuring glycemia twice a week in all animals as recently
described by us [14].
Animal Groups and AICAR Treatment
In order to investigate the effects of chronic pharmacological
AMPK activation on body composition and whole-body energy
balance, three weeks after STZ-induced diabetes, the animals were
further divided into the following 4 groups: Control, AICAR,
STZ, and STZ+A. Control (Con) animals were those non-diabetic
animals originally injected with saline instead of STZ that received
single daily saline injections for 7 consecutive days. The AICAR
(A) group consisted of rats that were non-diabetic controls that
received single daily IP AICAR injections (400 mg/kg BW) for 7
consecutive days. The STZ and STZ+A groups consisted of those
rats originally rendered diabetic by STZ injections and while the
former group received single daily IP injections of saline, the latter
group received single daily IP injections of AICAR (same dose as
the AICAR group) for 7 consecutive days. The AICAR dose
selected was based on previous unpublished experiments in which
we detected the minimum amount of the compound necessary to
consistently induce AMPK activation in peripheral tissue (e.g.
skeletal muscles, adipose tissue, and liver), as well as to cause an
anorexic response that was accompanied by reductions in
hypothalamic AMPK phosphorylation in rats [14,18]. In fact,
this study is a continuation of a recently published study in which
we used the exact same AICAR dose and tested its effects on
AMPK Regulation of Energy Balance in Diabetes
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muscle metabolism and glycemic control in insulin-deficient rats
[14]. AICAR or saline was always injected between 09:30 and
10:00 h. At the end of the AICAR-treatment period, the animals
were anaesthetized for tissue extraction and then immediately
euthanized [14].
Determination of Body Weight, Food Intake, Water
Intake, and Feed Efficiency
Body weight (BW) and food intake were monitored on a daily
basis. The animals were weighed everyday between 09:30 and
10:00 h and then the chow pellets remaining in the cages were
weighed. Food intake was also monitored once by using the
comprehensive laboratory animal monitoring system (CLAMS;
Columbus Instruments, Inc. Ohio, USA) and the values were
identical to those obtained by manual determinations. The
CLAMS is also equipped with an automated system that measures
volumetric drinking, which allowed us to monitor water intake in
individual cages. Feed efficiency was estimated by dividing the
gain of BW (g) by the energy consumed (kcal) over a specific time-
period [22]. In this study, feed efficiency was calculated during 7
days that preceded AICAR injection and also during the 7-day
AICAR injection-period and expressed as g/kcal/7 days.
Animal Dissection for Body Composition Analysis and
Determination of LBM
At the end of the AICAR-treatment period, all rats were
weighed, anesthetized (Ketamine/Xylazine 90 mg and 10 mg/
100 g B.W., respectively), decapitated, and exsanguinated. The
abdominal and thoracic cavities were then longitudinally incised
and the internal organs were exposed. The liver, kidneys, heart,
were carefully removed and individually weighed. Next, retroper-
itoneal (Retro) and subcutaneous (SC) inguinal (Ing) fat pads as
well as all remaining visible fat were thoroughly removed and
weighed. To assess the weight of the viscera, the stomach and
intestines were isolated and weighed separately. A longitudinal
anterior skin incision from neck to tail was then made. A scalpel
was used to detach the entire skin consisting exclusively of fur and
subcutaneous white adipose tissue (WAT) from the carcass of each
animal. A similar procedure was carried out to remove the skin
from the head. The head and body skins were weighed separately.
The mass of the carcass consisting of skeletal muscle and bones
combined with the skinned head, heart, kidneys, and liver was
used as LBM [23].
Determination of in vivo Metabolic Parameters
The CLAMS was also used to perform all automated in vivo
determinations as previously described [23]. Briefly, the CLAMS
measures oxygen consumption (VO2), carbon dioxide production
(VCO2), and respiratory exchange ratio (RER). Each cage is also
equipped with a system of infrared beams that detects animal
movement in the X and Z axes, which was used to determine
spontaneous ambulatory activity. Energy expenditure (heat) was
calculated by multiplying the calorific value
(CV=3.815+1.2326RER) by VO2. Measurements using the
CLAMS were performed during the last day of the AICAR-
treatment period. The animals were placed in the CLAMS at
09:00 immediately following saline or AICAR injections. The first
hour of data collected in the CLAMS was discarded, since it is the
time required for the rats to fully acclimatize to the cage
environment [23]. The rats were monitored for a 24 h-period
encompassing the light (07:00–19:00 h) and dark (19:00–07:00 h)
cycles.
Determination of Circulating Insulin and Leptin
Blood from all animals was collected by saphenous vein
bleeding and the serum was used to determine insulin (ELISA
kit, Cat # EZRMi-13k, from Millipore, Billerica, MA, USA) and
leptin (ELISA Rat leptin kit, Cat # 90040 from Crystal Chem Inc.
Downers Grove, IL, USA). All procedures were performed
according to instructions provided by the manufacturers of the
kits.
Determination of Content and Phosphorylation of
Proteins by Western Blot
Immediately after decapitation, the hypothalamus was dissected
using the optic tracts, the thalamus, and the mammillary body as
landmarks [18], and then quickly frozen in liquid nitrogen and
stored at 280uC. The tissues were homogenized in a buffer
containing 25 mM Tris-HCl and 25 mM NaCl (pH 7.4), 1 mM
MgCl2, 2.7 mM KCl, 1% Triton-X, and protease and phospha-
tase inhibitors (0.5 mM Na3VO4, 1 mM NaF, 1 mM leupeptin,
1 mM pepstatin, and 20 mM PMSF). Homogenates were centri-
fuged, the infranatant collected, and an aliquot was used to
measure protein concentration by the Bradford method. Samples
were diluted 1:1 (vol/vol) with 26Laemmli sample buffer, heated
to 95uC for 5 min, and subjected to SDS-PAGE. All primary
antibodies were used in a dilution of 1:1,000 except for P-AMPK
(1:500). Equal loading was confirmed by both GAPDH detection
and Ponceau staining of all membranes.
Statistical Analysis
Data were pooled from two independent experiments (N= 8
animals per group). Results are presented as means 6 SEM. One-
and Two-way ANOVA followed by Tukey’s multi-comparison
post-hoc tests were used to assess differences among groups.
Differences were considered statistically significant at P,0.05.
Results
Food Intake, BW, Feed Efficiency, and Water Intake
Food intake did not differ between control (27.1860.94 g/day)
and AICAR (27.8761.10 g/day) rats during the week that
preceded AICAR administration (Figure 1A and B). However,
food intake was consistently reduced by ,25% in rats injected
with AICAR (20.1760.85 g/day) when compared to controls
(26.6560.65 g/day) (Figure 1A and B). As expected, STZ rats
were hyperphagic and elicited ,1.4-fold increase in food intake
when compared to controls. Hyperphagia was not altered in STZ
rats treated with AICAR (Figure 1A and B). Body weight of
control and AICAR rats progressively increased throughout the
study from 314.0869.37 g and 324.5068.97 g to 364.92611.31
and 375.61611.50, respectively. At the week prior to AICAR
administration, all diabetic rats (STZ and STZ+AICAR) had
significantly lower (,25%) body weights than the non-diabetic
counterparts (control and AICAR rats), a condition that did not
change during the AICAR administration-period (Figure 1C and
D). In fact, STZ and STZ+AICAR rats did not gain any
significant amount of weight throughout the study (Figure 1C and
D) and feed efficiency was very low in diabetic rats either prior to
or during AICAR administration (Figure 1E), demonstrating that
the fuel ingested was not diverted towards growth or accretion of
fat mass. Water intake did not differ between control and AICAR-
treated rats either prior to (39.9763.35 and 34.5661.84 ml/day)
or after AICAR administration (Figure 1F). However, this variable
was increased by ,4.7- to 5.5-fold in diabetic rats either prior to
(170.32614.44 and 189.37611.19 ml/day) or after AICAR
administration (144.30620.40 and 184.96611.19 ml/day) when
AMPK Regulation of Energy Balance in Diabetes
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compared to control animals (Figure 1F). Hyperphagia and
polydipsia are hallmarks of T1D [2] and are in line with the
severe hyperglycemia and insulin deficiency that these animals
demonstrated [14].
Body Composition
While LBM did not differ between control (196.4265.96 g) and
AICAR-injected (197.7265.55 g) rats, this variable was signifi-
cantly reduced by ,54% in STZ rats. AICAR also had an LBM-
sparing effect, since in STZ+A rats this variable was only ,40%
lower than controls and significantly higher (,30%) than that of
STZ rats (Figure 2A). In order to assess the contribution of
oxidative and glycolytic skeletal muscles to the alterations in LBM
seen in STZ and STZ+A rats, we measured the masses of soleus
(Sol), extensor digitorum longus (EDL), and epitrochlearis (Epit)
muscles in all animals. These muscles were chosen because of their
wide range of reported fiber-type distributions. The percentages of
type I, type IIa, and type IIb in Sol, EDL, and Epit muscles are
84/16/0, 3/57/40 [24], and 15/20/65 [25], respectively. The
masses of the Sol (Figure 2B), EDL (Figure 2C), and Epit
Figure 1. Polyphagia and polydipsia of Streptozotocin (STZ)-induced diabetes is not affected by AICAR treatment. Time-course of
food intake (A) average food intake (B), time-course body weight (BW) (C), average BW (D), feed efficiency (E), and water (F) intake of control (Con,
saline-injected), AICAR-injected (A), STZ, and STZ plus AICAR (STZ+A) rats. Time-course graphs show data from animals monitored on a daily basis one
week prior to (days 1–7) and during AICAR administration (days 8–14). *P,0.05 vs. Con, STZ, and STZ+A. #P,0.05 vs. Con and A (Two-way ANOVA,
N = 8).
doi:10.1371/journal.pone.0071944.g001
AMPK Regulation of Energy Balance in Diabetes
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(Figure 2D) muscles did not differ between control and AICAR-
treated rats. However, in STZ rats the masses of all three muscles
were significantly reduced by 48% (Sol), 63% (EDL), and 56%
(Epit) when compared to controls. Interestingly, AICAR treatment
significantly attenuated the muscle-wasting effect of STZ-induce
insulin deficiency in Sol (Figure 2B) and EDL (Figure 2C), but not
in Epit (Figure 2D) muscles. In fact, the masses of the Sol and EDL
muscles of STZ rats treated with AICAR were 30% and 46%
lower than controls and significantly higher (,30% and 50%) than
that of STZ rats (Figures 2B and 2C), respectively. Because STZ
rats were hyperphagic and AICAR reduced food intake in control
rats (Figure 1A), we also measured the mass of the viscera in all
animals. This variable was found to be 35–40% increased in STZ
and STZ+A rats (Figure 2E). The significant increased viscera
mass of STZ rats was essentially because of the accumulated
undigested humidified chow in the gastrointestinal tract of these
hyperphagic and polydipsic animals (Figure 2E). Assessment of
adipose tissue mass also revealed that SC Ing and Retro fat pads
were reduced by 36% and 40% in AICAR-treated rats,
respectively, when compared to controls (Figure 3A and B). In
STZ rats, the masses of SC Ing and Retro fat pads were drastically
reduced, reaching values that corresponded to,10.5% (Figure 3A)
and ,0.5% (Figure 3B) of their controls, respectively. Interest-
ingly, while in non-diabetic rats AICAR reduced fat mass, in STZ
rats AICAR treatment attenuated fat loss; however, this occurred
in a depot-specific manner. In fact, while AICAR-treated STZ rats
had values of SC Ing fat mass ,1.9-fold (1.3960.25 g vs.
0.7360.16 g) higher than those of STZ rats (Figure 3A), no
significant differences were found with regards to Retro fat pad
masses between STZ and STZ+A rats (0.0260.01 g vs.
0.2960.16 g) (Figure 3B). We have also recently reported that
AICAR administration attenuated fat loss in the epidydimal fat
depot of STZ rats [14].
VO2, RER, Heat, and Ambulatory Activity
Given the profound changes that occurred in food intake and
body composition of STZ rats and the effects of AICAR treatment
on these variables, we assessed major parameters involved in the
regulation of whole-body energy metabolism. In this context, no
significant differences were found for VO2 between control and
AICAR-treated rats during the light and dark cycles (Figure 4A
and B). However, in STZ rats this variable was significantly
increased by 43% and 34% during the light and dark cycles,
respectively, when compared to control rats. Similar increments in
VO2 during the dark and light cycles were also found in STZ+A
rats, indicating that the effects of STZ-induced insulin deficiency
were not affected by AICAR treatment (Figure 4A and B).
Analysis of RER revealed that, on average, AICAR reduced this
variable from 0.92460.004 to 0.88560.01 during the light cycle
and from 0.95260.003 to 0.93360.004 during the dark cycle.
However, the RER-reducing effect of AICAR was clearly more
pronounced during the first 10 hours post injection (Figure 4C and
D). RER was also profoundly affected in diabetic rats. In fact,
RER of STZ rats was consistently reduced throughout the day and
actually eliminated the typical differences that exist between light
and dark cycles in control rats (Figure 4C and D). The average
RER of STZ rats was 0.86060.002 and 0.85460.002 during the
light and dark cycles, respectively. RER was further reduced upon
treatment of STZ rats with AICAR, reaching average values of
0.82260.004 during the light cycle and 0.82660.003 during the
dark cycle (Figure 4C and D). These data clearly show that
AICAR induced a shift towards whole-body fat oxidation not only
in non-diabetic but also in STZ rats. Energy expenditure
expressed as heat did not differ during the light and dark cycles
in control and AICAR-treated rats (Figure 4E and F). However, in
STZ rats, energy expenditure was significantly reduced by 14%
and 20% during the light and dark cycles, respectively, when
compared to controls. Treatment of STZ rats with AICAR raised
energy expenditure of these animals to values similar to those of
control rats (Figure 4E and F). Analysis of spontaneous ambulatory
activity also revealed no differences during the light and dark
cycles between control and AICAR-treated rats (Figure 4G and
H). In STZ rats, ambulatory activity was significantly reduced by
,51% and 48% during the light and dark cycles, respectively,
when compared to control rats (Figure 4G and H). AICAR
treatment raised ambulatory activity of STZ rats to values similar
to those of control rats during the light cycle. AICAR also
increased dark cycle ambulatory activity of STZ rats, but it still
remained 25% lower than control values (Figure 4G and H).
Content and Phosphorylation of AMPK, ACC, STAT3, and
SOCS3 in the Hypothalamus
Western blotting analysis revealed that control and AICAR rats
had similar rates of hypothalamic AMPK phosphorylation
(Figure 5A). However, in STZ rats, this variable was significantly
increased by ,1.9-fold and treatment of STZ rats with AICAR
reduced hypothalamic AMPK phosphorylation to values similar to
those of control rats (Figure 5A). Even though hypothalamic
AMPK phosphorylation was unaltered in non-diabetic rats treated
with AICAR, ACC phosphorylation was found to be markedly
reduced in these animals (Figure 5B). Furthermore, while ACC
phosphorylation increased by ,3-fold in the hypothalami of STZ
rats, treatment of these animals with AICAR potently reduced this
variable to values equivalent to ,28% of those of control rats
(Figure 5B). STAT3 phosphorylation did not differ between
control and AICAR rats, although it was significantly diminished
by ,32–34% in STZ and STZ +A rats. The hypothalamic
content of STAT3 was also clearly reduced in STZ and STZ+A
rats and AICAR did not affect this variable (Figure 5C). AICAR
treatment significantly reduced by ,67% hypothalamic SOCS3
content in non-diabetic rats, although it did not exert any effect on
this variable in STZ rats (Figure 5D).
Circulating Insulin and Leptin
As we have previously reported [14], insulin was almost
undetectable in the blood of STZ rats, which were also severely
hyperglycemic (29.860.8 mmol/l). Treatment of STZ rats with
AICAR did not cause any improvement in glycemia or
insulinemia in these animals [14]. With regards to serum leptin
levels, we found that non-diabetic AICAR-treated rats had ,1.7-
fold higher levels of this hormone than control rats
(6.1160.72 ng/ml vs. 3.6060.51 ng/ml). Conversely, leptin was
almost undetectable (0.2160.06 ng/ml) in the serum of STZ rats
(Figure 6). In STZ+A rats, leptin levels were slightly higher than in
STZ animals, although not reaching statistical significance
(Figure 6).
Discussion
Here, we provide novel evidence that 7 consecutive days of
in vivo AICAR treatment attenuated the loss of lean and fat masses
while increasing spontaneous physical activity and whole-body
energy expenditure in insulin-deficient rats. In non-diabetic rats,
AICAR increased circulating leptin, reduced hypothalamic
SOCS3 content, and exerted an anorexic effect. In insulin-
deficient rats, hypothalamic AMPK and ACC phosphorylation
were markedly increased and AICAR treatment completely
reversed this effect; however, it was not sufficient to prevented
AMPK Regulation of Energy Balance in Diabetes
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Figure 2. Treatment with AICAR attenuates the catabolic effects of streptozotocin (STZ)-induced diabetes on body composition.
Lean body mass (LBM) (A), soleus (Sol) (B), extensor digitorum longus (EDL) (C), and epitrochlearis (Epit) (D) muscles, and viscera (E) masses were
measured in control (Con, saline-injected), AICAR-injected (A), STZ, and STZ plus AICAR (STZ+A) rats at the end of the study. *P,0.05 vs. Con, A, and
STZ+A. #P,0.05 vs. Con, A, and STZ. `P,0.05 vs. Con and A. (One-way ANOVA, N = 8).
doi:10.1371/journal.pone.0071944.g002
Figure 3. Fat depot-specific anti-catabolic effect of AICAR in rats with streptozotocin (STZ)-induced insulin deficiency. Subcutaneous
(Sc) inguinal (Ing) fat (A) and retroperitoneal (Retro) fat (B) masses of control (Con, saline-injected), AICAR-injected (A), STZ, and STZ plus AICAR
(STZ+A) rats were extracted and quantified at the end of the study. *P,0.05 vs. Con, A, and STZ+A. #P,0.05 vs. Con, A, and STZ. `P,0.05 vs. Con,
STZ, and STZ+A (One-way ANOVA, N= 8).
doi:10.1371/journal.pone.0071944.g003
AMPK Regulation of Energy Balance in Diabetes
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hyperphagia in these animals. This was likely due to the fact that
while SOCS3 remained unaltered, STAT3 content and phos-
phorylation were markedly reduced in the hypothalami of insulin-
deficient rats, and these were not altered by AICAR treatment.
The anti-catabolic effects of AICAR on skeletal muscles of STZ
rats were fiber type-specific, since only muscles with relatively high
oxidative capacities (Sol and EDL) from STZ+A rats had
significantly higher mass values than those of STZ rats. Activation
Figure 4. Profile of oxygen consumption (VO2) (A and B), respiratory exchange ratio (RER) (C and D), energy expenditure (heat) (E
and F), and ambulatory activity (G and H) in control (Con, saline-injected), AICAR-injected (A), streptozotocin (STZ) diabetic, and
streptozotocin plus AICAR (STZ+A) rats. At the end of the AICAR administration-period all animals were placed in the CLAMS for 24 h. *P,0.05
vs. Con and A light. #P,0.05 vs. Con and A dark. `P,0.05 vs. Con light. ¥P,0.05 vs. Con dark. {P,0.05 vs. Con and A light. 1P,0.05 vs. Con, A, and
STZ light and dark. &P,0.05 vs. Con, A, and STZ+A dark. $P,0.05 vs. Con, A, and STZ+A dark. £- P,0.05 vs. Con, A, and STZ dark (Two-way ANOVA,
N = 8).
doi:10.1371/journal.pone.0071944.g004
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of AMPK is supposed to trigger catabolic processes to increase
intracellular ATP availability while switching off energy-demand-
ing anabolic processes such as protein sysnthesis [7,26,27].
Therefore, it seems counterintuitive that the treatment with an
AMPK-activating agent would actually reduce muscle wasting in
insulin-deficient rats. However, we have also recently reported that
treatment of STZ-induced diabetic rats with AICAR actually
attenuated AMPK phosphorylation in EDL and Epit muscles of
these animals [14]. It appears that the increase in glycogen content
promoted by AICAR treatment [14] minimized the stress of
glucose deprivation in EDL and EPI muscles of STZ rats, which in
turn attenuated the potential catabolic effects of glucose depriva-
tion-induced AMPK activation. Additionally, since glycogen is
highly hydrated and associated with three times its own weight in
water [28], the AICAR-induced increase in skeletal muscle
glycogen content can previously reported in STZ rats [14] can,
at least partially, account for the higher LBM found in AICAR-
treated STZ rats. Also, for the maintenance of BW despite the loss
of fat found in control rats treated with AICAR. STZ rats were
also lethargic and showed significantly reduced ambulatory
activity and 24 h energy expenditure; however, these conditions
were all reversed with AICAR treatment. Thus, it appears that the
anti-catabolic effects of AICAR on skeletal muscle had a favorable
impact on spontaneous physical activity and improved the ability
of the rats to cope with the dysfunctional alterations in glucose and
whole-body energy homeostasis caused by STZ-induced diabetes.
In this study we also show that AICAR exerted fat depot-
specific sparing effects in STZ rats, which was characterized by
attenuation of mass depletion in the SC Ing but not the Retro fat
depot in these animals. We have previously reported that the
epidydimal fat pad was drastically reduced in STZ rats and that
AICAR treatment also attenuated this effect [14]. These fat-
sparing effects of AICAR were only found in STZ rats, since fat
mass of non-diabetic rats receiving AICAR was actually reduced, a
finding also previously reported by us [18] and others [12]. The
fat-reducing effects in non-diabetic rats can be explained by the
fact that AICAR caused a 28% reduction in food intake in these
animals when compared to controls. AICAR treatment increased
circulating leptin and markedly reduced hypothalamic ACC
phosphorylation and SOCS3 content without affecting hypotha-
lamic AMPK phosphorylation in non-diabetic rats. These findings
are consistent with the suppression of food intake observed in these
Figure 5. AICAR treatment reduces AMPK and ACC phosphorylation but does not prevent the reduction in STAT3 content and
phosphorylation in the hypothalamus of STZ rats. At the end of the study, hypothalami were quickly dissected from control (Con, saline-
injected), AICAR-injected (A), streptozotocin (STZ), and STZ plus AICAR (STZ+A) rats and used for western blotting. Representative blots and
respective densitometric analyses of tissue homogenates probed for phosphorylated and total AMPK (A), phosphorylated and total ACC (B),
phosphorylated and total STAT3 (C), total SOCS3 and GAPDH (D). *P,0.05 vs. Con, A, and STZ+A. #P,0.05 vs. Con and A. `P,0.05 vs. Con STZ, and
STZ+A. 1P,0.05 vs. Con, A, and STZ. (One-way ANOVA, N = 4).
doi:10.1371/journal.pone.0071944.g005
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animals. However, since plasma levels of leptin are directly
proportional to fat mass, it is surprising that leptin was increased in
the blood of non-diabetic rats that reduced adiposity upon AICAR
treatment. In previous studies in which rats received daily AICAR
injections for up to 4 and 8 consecutive weeks, we found that
adiposity and leptinemia were both consistently diminished in
these animals [18]. In spite of that, rats chronically treated with
AICAR showed an exacerbated anorexic response to exogenous
leptin, which indicated increased sensitivity to this hormone [18].
In this study, rats received AICAR injections for a much shorter
period of time (7 consecutive days only) and this could be the
reason for these apparently discrepant findings with regards to
leptinemia. It is possible that AICAR initially increases circulating
leptin and potentiates the anorexic response to this hormone.
However, with continued treatment and as significant reductions
in adiposity take place, circulating levels of leptin actually drop
and reduce the anorexic response to AICAR treatment. In fact, we
have previously reported that the anorexic effect of AICAR was
much more pronounced in the initial stages (1 to 2 weeks) of
treatment with this drug and became progressively attenuated as
the treatment extended towards 8 weeks [18]. This could indeed
reflect a time-dependent effect of AICAR treatment on adiposity
and leptin release. However, additional studies are required to
further explore these possibilities.
STZ rats had markedly elevated levels of hypothalamic AMPK
and ACC phosphorylation, a condition that was accompanied by a
2-fold increase in food intake when compared to control rats. Also,
these animals had drastic reductions in adiposity and almost
undetectable levels of leptin in the circulation. Previous studies
have demonstrated that leptin inactivates AMPK in the hypothal-
amus, which, in turn, causes dephosphorylation/activation of
ACC and leads to an anorexic response [19,29]. This is consistent
with our findings that hypoleptinemic STZ rats actually had
increased hypothalamic AMPK and ACC phosphorylation and
were clearly hyperphagic. ACC phosphorylation/de-activation
reduces malonyl-CoA synthesis and low levels of this lipid
intermediate in the hypothalamus have been associated with
increased food intake [30,31]. Surprisingly, we found that STZ
rats remained hyperphagic even though hypothalamic AMPK and
ACC phosphorylation were markedly reduced by AICAR
treatment. This demonstrated that the activation of ACC in the
hypothalamus of insulin- and leptin-deficient rats was not sufficient
to inhibit food intake, since alterations in other key signaling steps
involved in the regulation of feeding behavior could also be
drastically affected in these animals. In fact, further analyses
revealed that STAT3 content and phosphorylation were signifi-
cantly reduced in STZ rats. STAT3 plays a major role in
mediating the effects of anorexigenic signals in the arcuate and
paraventricular hypothalamic nuclei [19,29]. Therefore, reduced
content and phosphorylation of STAT3 in the hypothalamus must
have allowed orexigenic signals to prevail even though AMPK and
ACC phosphorylation were potently reduced by AICAR treat-
ment in STZ rats. Furthermore, a major difference between
control rats that did elicit an anorexic response to AICAR and
STZ rats that did not was that the hypothalamic content of
SOCS3 in the former was significantly reduced while in the latter
it was not. SOCS3 is a feedback inhibitor of the Jak-Stat pathway
that prevents STAT3 activation. SOCS3 overexpression in the
hypothalamus induces leptin resistance and obesity [32], while its
inactivation in the hypothalamus has been shown to enhance the
response to endogenous satiety signals [33] and attenuate obesity
in mice fed a high-fat diet [34–36]. In this context, it appears that
the combination of reduced STAT3 and elevated SOCS3 content
prevented AICAR treatment from inducing an anorexigenic
response in STZ rats. This indicates that the anorexic effects of
systemic AICAR administration are lost under conditions of
deficiency of the two major satiety hormones insulin and leptin.
However, since AICAR rapidly appears in cortical regions of the
brain when administered systemically (i.p. and i.v.) to rats and
increases the concentration of adenosine metabolites in these areas
[37], we cannot discard the possibility that AICAR modulates the
content and activity of STAT3 and SOCS3 independently of
leptin and AMPK/ACC signaling in the hypothalamus. In fact, it
has been well-documented that hypothalamic functions can be
regulated by the activation of adenosine and/or purinergic
receptors [38]. In this context, by activating various adenosine
and purinergic receptors, AICAR-derived adenosine metabolites
could lead to regulation of STAT3, SOCS3, as well as other
signaling steps involved in the control of food intake in a leptin-
and AMPK/ACC-independent manner. Thus, further studies are
required to address these possibilities.
In summary, our data provides novel evidence that the AMPK
activator AICAR exerted muscle- and fat-depot-specific anti-
catabolic effects and increased spontaneous physical activity and
energy expenditure in insulin-deficient rats. AICAR reduced
hypothalamic ACC phosphorylation and SOCS3 content and
exerted an anorexic effect in non-diabetic rats. However, AICAR
did not affect hyperphagia in insulin-deficient rats, even though it
significantly reduced AMPK and ACC phosphorylation in the
hypothalamus of these animals. These findings indicate despite not
preventing hyperphagia, the systemic effects of AICAR treatment
ameliorated some of the dysfunctional metabolic alterations of
T1D, which could be beneficial for the treatment of this disease.
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Figure 6. Circulating leptin is significantly increased in AICAR-
treated non-diabetic rats, but not in STZ-induced diabetic rats.
Blood was collected at the end of the treatment period from control
(Con, saline-injected), AICAR-injected (A), streptozotocin (STZ) diabetic,
and streptozotocin plus AICAR (STZ+A) rats and subsequently assayed
for leptin. *P,0.05 vs. Con, STZ, and STZ+A; #P,0.05 vs. Con and A
(One-way ANOVA, N= 8).
doi:10.1371/journal.pone.0071944.g006
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